Drugs / Insulin Lispro-aabc
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | LYUMJEV | — | 2021-08-13 – 2022-10-14 | fda.gov ↗ |
| Approved | US (FDA) | LYUMJEV | — | 2020-06-15 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06370715 | Apr 2024 → Sep 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07090824 Comparator | Oct 2025 → May 2026 | type 1 diabetes mellitus | Stanford University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Lispro-aabc | “Commercially available U-100 Lyumjev (insulin lispro-aabc) administered unmodified as comparator.” NCT07090824 ↗ |
| Known as | Lyumjev | “Commercially available U-100 Lyumjev (insulin lispro-aabc) administered unmodified as comparator.” NCT07090824 ↗ |
| Route | Subcutaneous | “Administered SC” NCT06370715 ↗ |